Nxera Pharma to Receive US$35 Million from Neurocrine Biosciences upon Positive Phase 2 Data for Partnered Schizophrenia Candidate NBI-1117568
01 sept. 2024 19h30 HE
|
Nxera Pharma
Tokyo, Japan and Cambridge, UK, 2 September 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – announces that it will receive a...
Nxera Pharma Notes Positive Phase 2 Data for Partnered Schizophrenia Candidate NBI-1117568
28 août 2024 07h07 HE
|
Nxera Pharma
NBI-1117568 is an oral, muscarinic M4 selective receptor agonist discovered by Nxera advancing through clinical development under a multi-program collaboration with Neurocrine BiosciencesThe...
Nxera Pharma Operational Highlights and Consolidated Results for the Second Quarter and First Half 2024
09 août 2024 02h30 HE
|
Nxera Pharma
Tokyo, Japan and Cambridge, UK, 9 August 2024 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the second...
Nxera Pharma Webinar Presentation for Q2 FY2024 Financial Results
09 juil. 2024 07h14 HE
|
Nxera Pharma
Tokyo, Japan and Cambridge, UK, 9 July 2024 - Nxera Pharma Co. Ltd (“Nxera”; TSE 4565) will announce its earnings results and present operational highlights for the 6 months ended 30 June 2024 on...
Nxera Pharma Receives US$10 Million from AbbVie as Collaboration Targeting Neurological Diseases Achieves First R&D Milestone
26 juin 2024 19h05 HE
|
Nxera Pharma
Tokyo, Japan and Cambridge, UK, 27 June 2024 - Nxera Pharma Co. Ltd (“Nxera”; TSE 4565), announces that it has reached an important R&D milestone under its multi-target discovery collaboration...
Nxera Pharma Publishes its Annual and ESG Reports for the Year ended 31 December 2023
18 juin 2024 03h55 HE
|
Nxera Pharma
Tokyo, Japan and Cambridge, UK, 18 June 2024 – Nxera Pharma (“Nxera” or “the Company”; TSE 4565), today announces the publication of its Annual Report and its Environment, Social & Governance...
Nxera Pharma to Receive $4.6 Million in Milestone Payments from Centessa Pharmaceuticals
30 mai 2024 02h35 HE
|
Nxera Pharma
Tokyo, Japan and Cambridge, UK, 30 May 2024 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) today announced that it expects to receive $4.6 million in milestone payments from Centessa...
Nxera Pharma and PrecisionLife Expand Strategic R&D Partnership into New Therapeutic Area
30 mai 2024 02h30 HE
|
Nxera Pharma
Expansion of existing partnership will utilize novel insights into causal biology within auto-immune disorders to identify novel targets for drug discovery Tokyo, Japan, Oxford and Cambridge,...
Nxera Pharma’s partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults
09 mai 2024 02h35 HE
|
Nxera Pharma
Tokyo, Japan and Cambridge, UK, 9 May 2024 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) notes that its partner Neurocrine Biosciences Inc. (“Neurocrine”; Nasdaq: NBIX), a leading...
Nxera Pharma Operational Highlights and Consolidated Results for the First Quarter 2024
09 mai 2024 02h30 HE
|
Nxera Pharma
Tokyo, Japan and Cambridge, UK, 9 May 2024 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the first...